Stonepine Capital Management LLC recently announced the acquisition of new stake in Evolus Inc (NASDAQ:EOLS). The institutional investor has increased its shareholding in the Healthcare company by 14.93% to 5.18 million shares with purchase of 0.67 million shares. This fresh investment now brings its stake to 9.06% valued currently at $49.05 million. In addition, Perceptive Advisors LLC raised its holdings by 1.6 million to 3.09 million shares. And The Vanguard Group, Inc. has lifted its position by 39.83% or 0.74 million shares – to 2.58 million shares.
With over 0.47 million Evolus Inc (EOLS) shares trading Friday and a closing price of $9.96 on the day, the dollar volume was approximately $4.71 million. The shares have shown a positive half year performance of 34.96% and its price on 12/22/23 lost nearly -0.20%. Currently, there are 56.26M common shares owned by the public and among those 44.26M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Insiders at the company have transacted a total of 30 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 20 of these insider trades were purchases, accounting for 914,631 shares. Insider sales of the common stock occurred on 10 occasions, with total insider shares sold totaling 5,835,779 shares.
The top 3 mutual fund holders in Evolus Inc are Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and Schroder US Smaller Companies Fun. Vanguard Total Stock Market ETF owns 1.64 million shares of the company’s stock, all valued at over $15.54 million. iShares Russell 2000 ETF bought 489.0 shares to see its total holdings expand to 0.99 million shares valued at over $9.41 million and representing 1.74% of the shares outstanding. Schroder US Smaller Companies Fun bought 41210.0 shares to bring its total holdings to over 0.78 million shares at a value of $7.37 million. Schroder US Smaller Companies Fun now owns shares totaling to 1.36% of the shares outstanding.
Shares of Evolus Inc (NASDAQ: EOLS) opened at $10.00, up $0.02 from a prior closing price of $9.98. However, the script later moved the day high at 10.28, down -0.20%. The company’s stock has a 5-day price change of 0.61% and 10.79% over the past three months. EOLS shares are trading 32.62% year to date (YTD), with the 12-month market performance up to 46.69% higher. It has a 12-month low price of $6.51 and touched a high of $11.49 over the same period. EOLS has an average intraday trading volume of 681.15K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.07%, 12.38%, and 13.50% respectively.
Institutional ownership of Evolus Inc (NASDAQ: EOLS) shares accounts for 76.45% of the company’s 56.26M shares outstanding. Mutual fund holders own 36.46%, while other institutional holders and individual stakeholders account for 55.92% and 20.55% respectively.
It has a market capitalization of $569.21M and a beta (3y monthly) value of 1.58. The earnings-per-share (ttm) stands at -$1.11. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.82% over the week and 3.71% over the month.
Analysts forecast that Evolus Inc (EOLS) will achieve an EPS of -$0.09 for the current quarter, -$0.09 for the next quarter and -$0.32 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.12 while analysts give the company a high EPS estimate of -$0.06. Comparatively, EPS for the current quarter was -$0.14 a year ago. Earnings per share for the fiscal year are expected to increase by 40.46%, and 17.61% over the next financial year. EPS should grow at an annualized rate of 16.50% over the next five years, compared to -37.50% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 8 brokerage firm advisors rate Evolus Inc (EOLS) as a “Strong Buy” at a consensus score of 1.25. Specifically, 7 Wall Street analysts polled rate the stock as a buy, while 1 of the 8 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the EOLS, a number of firms have released research notes about the stock. Needham stated their Buy rating for the stock in a research note on June 23, 2022, with the firm’s price target at $18.
